Medline (NasdaqGS:MDLN) Q4 2025 Earnings call February 25, 2026 09:30 AM ET Company ParticipantsAndrew Obin - Managing DirectorDavid Larsen - Managing DirectorDavid Roman - Managing DirectorElizabeth Anderson - Senior Managing DirectorEric Coldwell - Managing DirectorGlen Santangelo - Managing DirectorJim Boyle - CEOKaren King - Global Head of Investor RelationsLisa Gill - Managing DirectorMichael Cherny - Senior Managing DirectorMike Drazin - CFOPatrick Donnelly - Managing DirectorPatrick Wood - Managing D ...

Delivered strong full year 2025 resultsCompleted Initial Public OfferingIntroduced full year 2026 guidanceFourth quarter net sales of $7.8 billion, an increase of 14.8%Fourth quarter net income of $180 million, a decrease of 37.7%Fourth quarter Adjusted EBITDA1 of $805 million, approximately flatFull year net sales of $28.4 billion, an increase of 11.5%Full year net income of $1.2 billion, a decrease of 3.6%Full year Adjusted EBITDA1 of $3.5 billion, an increase of 3.2% NORTHFIELD, Ill., Feb. 25, 2026 (GLOB ...

Shares of West Pharmaceutical Services (WST) have gained 1.9% over the past four weeks to close the last trading session at $241.12, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $319.07 indicates a potential upside of 32.3%.The average comprises 14 short-term price targets ranging from a low of $265.00 to a high of $375.00, with a standard deviation of $28.52. While the lowes ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades: Baird upgraded Henry Schein (HSIC) to Outperform from Neutral with a price target of $100, up from $78. The firm believes the bias across its dental names remains to the upside.UBS upgraded BlackRock (BLK) to Buy from Neutral with a $1,280 price target. The upgrade is supported by strong Q4 results, positive comme ...

Core Insights - Medline Inc. will present at the Barclays 28th Annual Global Healthcare Conference on March 11, 2026, at 9:30am ET [1] - The presentation will be available via webcast on Medline's Investor Relations website, with a replay accessible for six months post-event [2] Company Overview - Medline is the largest provider of medical-surgical products and supply chain solutions, serving all points of care [3] - The company has a broad product portfolio, resilient supply chain, and leading clinical solutions aimed at improving healthcare providers' clinical, financial, and operational outcomes [3] - Headquartered in Northfield, Illinois, Medline employs over 43,000 people globally and operates in more than 100 countries [3]

Core Insights - Medline Inc. will present at the Barclays 28th Annual Global Healthcare Conference on March 11, 2026, at 9:30am ET [1] - The presentation will be accessible via a webcast on Medline's Investor Relations website, with a replay available for six months post-event [2] Company Overview - Medline is the largest provider of medical-surgical products and supply chain solutions, serving all points of care [3] - The company has a broad product portfolio, resilient supply chain, and leading clinical solutions aimed at improving healthcare providers' clinical, financial, and operational outcomes [3] - Headquartered in Northfield, Illinois, Medline employs over 43,000 people globally and operates in more than 100 countries [3]

Core Insights - West Pharmaceutical Services (WST) reported revenue of $805 million for the quarter ended December 2025, reflecting a year-over-year increase of 7.5% and surpassing the Zacks Consensus Estimate by 1.35% [1] - The company's EPS for the quarter was $2.04, up from $1.82 in the same quarter last year, resulting in an EPS surprise of 11.21% compared to the consensus estimate of $1.83 [1] Financial Performance Metrics - Organic revenue growth was reported at 3.3%, exceeding the average analyst estimate of 1.8% [4] - Net sales from contract-manufactured products reached $143.2 million, slightly below the average estimate of $144.45 million, but showing a year-over-year increase of 6.2% [4] - Net sales from proprietary products amounted to $661.8 million, surpassing the average estimate of $648.56 million and representing a 7.8% increase compared to the previous year [4] - Gross profit from proprietary products was $285.7 million, exceeding the average estimate of $257.16 million [4] - Gross profit from contract-manufactured products was reported at $18.2 million, which fell short of the average estimate of $25.76 million [4] Stock Performance - Over the past month, shares of West Pharmaceutical have declined by 10.5%, while the Zacks S&P 500 composite experienced a minor decline of 0.3% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Core Insights - Rockwell Medical has been recognized as a Great Place to Work for the fourth consecutive year, highlighting the importance of its employees in driving the company's success [1][1][1] Company Overview - Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company focused on developing, manufacturing, and distributing hemodialysis products for dialysis providers globally [1][1] - The company aims to provide high-quality products and exceptional customer service to dialysis clinics and patients [1][1] Employee Recognition - The Great Place to Work certification is based on employee feedback regarding their workplace experience, emphasizing a high-trust environment [1][1] - Rockwell Medical's Vice President of Human Resources stated that the recognition motivates the company to foster a supportive and empowering workplace culture [1][1] Commitment to Innovation - The company is dedicated to enhancing its products, processes, and workforce to drive long-term innovation and value [1][1] - Rockwell Medical is focused on delivering reliable and high-quality services to the dialysis community, which is crucial for patients with end-stage kidney disease [1][1]

Core Viewpoint - Embecta Corp. has appointed Devdatt Kurdikar as Chairman of the Board and Dr. Claire Pomeroy as Lead Independent Director, marking a significant leadership transition as the company aims to evolve from a focus on insulin delivery to a broader medical supplies company [1][3]. Group 1: Leadership Changes - Devdatt Kurdikar, previously leading the diabetes care business at BD, has been elected as Chairman of the Board following the retirement of LTG (Ret.) David F. Melcher [1][2]. - Dr. Claire Pomeroy, who has been on the Board since its inception in 2022, will continue her role as Lead Independent Director while also chairing the Corporate Governance and Nominating Committee [3][4]. Group 2: Company Vision and Strategy - Kurdikar expressed commitment to driving the company's transformation into a broad-based medical supplies entity, emphasizing the progress made since its launch as an independent company nearly four years ago [3]. - Dr. Pomeroy highlighted the Board's diverse experience and shared purpose, expressing confidence in advancing Embecta's mission to empower people with diabetes and improve lives through innovative solutions [4]. Group 3: Company Background - Embecta is a global company with a 100-year legacy in insulin delivery, now focusing on becoming a comprehensive medical supplies provider, supported by approximately 2,000 employees worldwide [4].

Company Overview - Becton, Dickinson and Company (BDX) is based in Franklin Lakes, New Jersey, with a market capitalization of $48.9 billion, focusing on the development, manufacturing, and sale of medical supplies, devices, laboratory equipment, and diagnostic products for various healthcare sectors worldwide [1] Stock Performance - BDX shares have underperformed the broader market, declining 25.2% over the past 52 weeks and 11.5% year-to-date (YTD), while the S&P 500 Index has returned 14.4% over the past year and increased by 1.4% in 2026 [2] - The stock has also lagged behind the State Street Healthcare Select Sector SPDR ETF (XLV), which rose by 6.2% over the past 52 weeks [3] Earnings Report - Following the Q4 2025 earnings release on February 9, BDX shares fell by 1.3%. The company's revenue increased by 1.6% year-over-year to $5.3 billion, surpassing consensus estimates. Adjusted EPS was $2.91, beating estimates by 3.2%. However, life sciences revenue of $766 million fell significantly short of the consensus estimate of $1.3 billion [4] Future Earnings Expectations - For the fiscal year ending in September 2026, analysts project BDX's EPS to grow by 2.9% year-over-year to $14.82 on a diluted basis. The company has a strong earnings surprise history, having exceeded consensus estimates in each of the last four quarters [5] Analyst Ratings - Among 14 analysts covering BDX stock, the consensus rating is a "Moderate Buy," consisting of six "Strong Buy" ratings and eight "Holds." This rating configuration has become more bullish over the past month, with "Strong Buy" ratings increasing from four to six [6] Price Target - JP Morgan analyst Robert Marcus maintained a "Neutral" rating for BDX and lowered the price target from $190 to $175. The mean price target of $204 indicates an upside potential of 18.8% from current market prices, while the highest target of $232 suggests a potential rally of up to 35.1% [8]